5 news items
Galapagos And Adaptimmune Enter Clinical Collaboration To License Next-Generation TCR T-Cell Therapy For Cancer Using Decentralized Manufacturing Platform
ADAP
GLPG
30 May 24
Adaptimmune to receive initial payments of $100 million, comprising $70 million upfront and $30 million of R&D funding, option exercise
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications
ADAP
GLPG
30 May 24
, comprising $70 million upfront and $30 million of R&D funding, option exercise fees of up to $100 million, additional development and sales
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
ADAP
GLPG
30 May 24
million, comprising $70 million upfront and $30 million of R&D funding, option exercise fees of up to $100 million, additional development and sales
Galapagos Q1 EPS €1.40 Vs €0.40 YoY; Revenue €62.4 Million Vs €58.6 Million YoY
GLPG
2 May 24
revenues are booked in total net revenues.R&D expenses in the first three months of 2024 amounted to €71.6 million
Galapagos reports first quarter 2024 financial results
GLPG
2 May 24
potentially best-in-class cell therapy and small molecule R&D pipeline comprising four clinical assets and >15 discovery
- Prev
- 1
- Next